Update on raloxifene: Role in reducing the risk of invasive breast cancer in postmenopausal women

Breast Cancer: Targets and Therapy

Volumn 3, Issue , 2011, Pages 127-137

  Vogel, Victor G ^a  

^a GEISINGER HEALTH SYSTEM   (United States)

Author keywords

Chemoprevention; Raloxifene; Risk reduction; Selective estrogen receptor modulators (SERMs)

Indexed keywords

EID: 84924914428     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S11288     Document Type: Review

References (37)

1. Vogel VG. Managing the risk of breast cancer in postmenopausal women: introduction. Menopause. 2008;15(4 Suppl):779-781.
2. Gierach G, Vogel VG. Epidemiology of breast cancer. In: Singletary SE, Robb GL, Hortobagyi GN, editors. Advanced Therapy of Breast Disease. 2nd ed. Hamilton, ON: BC Decker, Inc; 2004:58-83.
3. Reeves K, Hudson A, Vogel VG. Epidemiology of breast cancer. In: Bland KI, Copeland EM, editors. The Breast: Comprehensive Management of Benign and Malignant Disease. 4th ed. Philadelphia, PA: Elsevier; 2009:349-369.
4. Velie EM, Nechuta S, Osuch JR. Lifetime reproductive and anthropometric risk factors for breast cancer in postmenopausal women. Breast Dis. 2005;24:17-35.
5. Santen RJ, Mansel R. Benign breast disorders. N Engl J Med. 2005;353: 275-285.
6. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353:229-237.
7. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the Cancer and Steroid Hormone Study. Am J Hum Genet. 1991;48: 232-242.
8. Narod SA, Offit K. Hereditary breast cancer: prevention and management of hereditary breast cancer. J Clin Oncol. 2005;23:1656-1663.
9. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-1886.
10. Costantino JP, Gail MH, Pee D. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541-1548.
11. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98:1204-1214.
12. Chlebowski RT, Anderson GL, Lane DS, et al. Women's Health Initiative Investigators. Predicting risk of breast cancer in postmenopausal women by hormone receptor. J Natl Cancer Inst. 2007;99: 1695-1705.
13. Cummings SR, Tice JA, Bauer S, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst. 2009;101:384-398.
14. Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat. 2005;94:115-122.
15. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density: a hormonally responsive risk factor for breast cancer. J Br Menopause Soc. 2006;12:186-193.
16. Kerlikowske K, Ichikawa L, Miglioretti DL, et al; National Institutes of Health Breast Cancer Surveillance Consortium. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst. 2007;99: 386-395.
17. Chen J, Pee D, Ayyagari R, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst. 2006;98:1215-1226.
18. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296-300.
19. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
20. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1study. J Natl Cancer Inst. 2005;97: 1652-1662.
21. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P; Italian Tamoxifen Study Group. Tamoxifen for breast cancer among hysterectomised women. Lancet. 2002;359:1122-1124.
22. Veronesi U, Maisonneuve P, Rotmensz N, et al; Italian Tamoxifen Study Group. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst. 2003;95:160-165.
23. Veronesi U, Maisonneuve P, Rotmensz N, et al; Italian Tamoxifen Study Group. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007;99:727-737.
24. Cuzick J, Forbes J, Edwards R, et al; IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817-824.
25. Cuzick J, Forbes JF, Sestak I, et al; International Breast Cancer Intervention Study I Investigators. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272-282.
26. Powles TJ, Ashley S, Tidy A, Smith I, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded Tamoxifen Breast Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:283-290.
27. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 1999;281:2189-2197.
28. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 2001;65:125-134.
29. Martino S, Cauley JA, Barrett-Connor E, et al; CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751-1761.
30. Barrett-Connor E, Mosca L, Collins P, et al; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125-137.
31. Vogel VG, Costantino JP, Wickerham DL, et al. National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727-2741.
32. Vogel VG, Costantino JP, Wickerham DL, et al. National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res. 2010;3: 696-706.
33. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2742-2751.
34. Hortobagyi GN, Brown PH. Two good choices to prevent breast cancer: great taste, less filling. Cancer Prev Res. 2010;3:681-685.
35. Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) Trial. Expert Rev Anticancer Ther. 2009;9:51-60.
36. Visvanathan K, Chlebowski RT, Hurley P, et al; American Society of Clinical Oncology. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009;27:3235-3258.
37. Vogel VG. Raloxifene: a second-generation selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women. Women's Health. 2007;3:139-153.